Vivus' $110m 'band-aid' could cost $147.1m
This article was originally published in Scrip
Vivus is leveraging sales from the weight loss drug Qsymia (phentermine and topiramate) that it has not yet been able to achieve in order to borrow up to $110 million that will finance its commercial programs and other unspecified expenses.
You may also be interested in...
Lilly, Allergan and Biohaven plan to launch oral drugs for on-demand treatment of migraine attacks in the first quarter, hoping to harness a large market where new preventive therapies are already competing for patients.
Private Company Edition: VC deals fell short of the record-breaking level seen in 2018 and financings may slow a bit more in 2020. Also, UPMC and Frazier close new VC funds, and Emendo raises $61m for gene-editing platform.
Monia told Scrip at the J.P. Morgan Healthcare Conference that the company will be more selective about partnerships going forward and build commercial capabilities to market Ionis-owned drugs.